Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years

Details

• Journal Article:
  Morbidity and Mortality Weekly Report (MMWR)
• Description:
  Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years. In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.
• Subjects:
  Herpes Zoster Herpes Zoster Vaccine Humans Licensure Middle Aged
• Source:
  MMWR. Morbidity and mortality weekly report. 2011; 60(44):1528.
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  22071592
• Document Type:
  Journal Article
• Name as Subject:
  United States. Food and Drug Administration. ; United States. Food and Drug Administration.
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  60
• Issue:
  44
• Collection(s):
  Guidelines and Recommendations Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:d775ad1e77b3ff5ca9e23b11bc84c98055729b38254e33550c6cb132aca8e19994525b8200a60a58d472f9e8aa81a111b014c5bfec43415b7fc5ab3db5dd202a
• Download URL:
  https://stacks.cdc.gov/view/cdc/7468/cdc_7468_DS1.pdf
• File Type:
  [PDF - 1.32 MB ]